Research has recently been undertaken to characterize the clinical course of COVID-19 among people with inflammatory bowel disease, and to evaluate associations between specific clinical characteristics, and immunosuppressant treatments on COVID-19 outcomes.A large registry: Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) has been established to monitor outcomes of IBD patients with confirmed COVID-19. 525 cases from 33 countries were identified (Median age 43 years, 53% men). Thirty-seven patients (7%) had severe COVID-19, 161 (31%) were hospitalized, and 16 patients died (3% case fatality rate). Age-standardised mortality ratios for IBD patients were 1.8 (95% confidence interval [CI] 0.9-2.6), 1.5 (95% CI 0.7-2.2), and 1.7 (95% CI 0.9-2.5) relative to data from China, Italy, and the US, respectively. Risk factors for severe COVID-19 were advanced age, ≥2 comorbidities , treatment with systemic corticosteroids (OR 6.9, 95% CI 2.3-20.5), and sulfasalazine or 5-aminosalicylate use (OR 3.1, 95% CI 1.3-7.7). TNF antagonist treatment was not associated with severe COVID-19 (aOR 0.9, 95% CI 0.4-2.2). More details of the study, published in the journal Gastroenterology, can be viewed here.